\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesIMPORTANT UPDATE
The deadline date of the call, indicated in the work programme with 16 January 2025, is changed to 11 February 2025.
HORIZON-MISS-2024-CIT-01: Changing urban spaces and mindsets to accelerate the transition to climate neutrality
HORIZON-MISS-2024-CIT-01-01: Rethinking urban spaces towards climate neutrality
HORIZON-MISS-2024-CIT-01-02: Zero-pollution cities
HORIZON-MISS-2024-CIT-01-03: Mobility Management Plans and Behavioural Change
HORIZON-MISS-2024-CIT-01-04: Integrated per-urban areas in the transition towards climate neutrality
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
